LEI-101 is a novel, orally bioavailable and peripherally restricted selective cannabinoid CB2 receptor agonist References: Mukhopadhyay P, Baggelaar M, Erdelyi K, Cao Z, Cinar R, Fezza F, Ignatowska-Janlowska B, Wilkerson J, van Gils N, Hansen T, Ruben M, Soethoudt M, Heitman L, Kunos G, Maccarrone M, Lichtman A, Pacher P, Van der Stelt M. The novel, orally available and peripherally restricted selective cannabinoid CB2 receptor agonist LEI-101 prevents cisplatin-induced nephrotoxicity. Br J Pharmacol. 2016 Feb;173(3):446-58. doi: 10.1111/bph.13338. Epub 2016 Jan 15. PubMed PMID: 26398481; PubMed Central PMCID: PMC4728411.

纯度：≥98%

CAS：1228660-00-1